ISOREA AB Secures €2.5 Million in Non-Dilutive Funding to Accelerate Alzheimer’s Blood Test Development
ISOREA AB is pleased to announce that it has been awarded approximately 25 million SEK (€2.5 million) in non-dilutive soft funding from the Bulgarian Ministry of Innovation and Growth, through its wholly owned subsidiary ISOREA Bulgaria EOOD. The funding was granted under the “Research, Innovation and Digitalisation for Smart Transformation” programme, following ISOREA’s Seal of Excellence from the EIC Accelerator.
This funding marks a significant milestone for ISOREA and will substantially accelerate the development and clinical validation of the company’s early Alzheimer’s disease risk detection blood test, while meaningfully reducing both technical and investment risk.
The achievement reflects the strong leadership and dedication of ISOREA’s CEO/VD, Dr. Sourav Prasanna Mukherjee, and COO, Dr. Sanchali Gupta, as well as the close and effective collaboration with ISOREA’s Bulgarian partner New-I, led by Mr. Anton Todorov and Ms. Zhechka Kalinova.
As part of this development, Dr. Sanchali Gupta has been appointed Managing Director of ISOREA Bulgaria EOOD by the ISOREA AB Board, led by Chairperson Prof. Roman Zubarev. She will oversee the execution of the funded project with the support of the broader ISOREA team.
With this funding secured, ISOREA is well positioned to advance its diagnostic programs toward market readiness. The company welcomes interest from investors seeking to participate in the next phase of ISOREA’s growth.